APOE and cardiovascular disorder: The knowledge gained from genotype studies of Apolipoprotein E (ApoE) variants in the population has been patented for commercial exploitation in a wide variety of conditions, ranging from the role of ApoE in determining the susceptibility to early-onset Alzheimer’s [9], the likely effectiveness of cholinomimetic treatment in patients with Alzheimer’s [10], the predisposition to lipoprotein abnormalities and cardiovascular disease and the predisposition to prostate cancer [11].